201 related articles for article (PubMed ID: 30684504)
1. Intact bioactivities and improved pharmacokinetic of the SL335-IFN-β-1a fusion protein that created by genetic fusion of SL335, a human anti-serum albumin fab, and human interferon-β.
Ji SI; Park JH; You HG; Chi HJ; Bang YW; Cha SH
Immunol Lett; 2019 Mar; 207():46-55. PubMed ID: 30684504
[TBL] [Abstract][Full Text] [Related]
2. Isolation of human anti-serum albumin Fab antibodies with an extended serum-half life.
Kang HJ; Kim HJ; Cha SH
Immunol Lett; 2016 Jan; 169():33-40. PubMed ID: 26593745
[TBL] [Abstract][Full Text] [Related]
3. Structural basis of serum albumin recognition by SL335, an antibody Fab extending the serum half-life of protein therapeutics.
Cho SY; Han J; Cha SH; Yoon SI
Biochem Biophys Res Commun; 2020 Jun; 526(4):941-946. PubMed ID: 32284170
[TBL] [Abstract][Full Text] [Related]
4. Optimal expression of a Fab-effector fusion protein in Escherichia coli by removing the cysteine residues responsible for an interchain disulfide bond of a Fab molecule.
Kang HJ; Kim HJ; Jung MS; Han JK; Cha SH
Immunol Lett; 2017 Apr; 184():34-42. PubMed ID: 28216260
[TBL] [Abstract][Full Text] [Related]
5. N-terminally PEGylated human interferon-beta-1a with improved pharmacokinetic properties and in vivo efficacy in a melanoma angiogenesis model.
Baker DP; Lin EY; Lin K; Pellegrini M; Petter RC; Chen LL; Arduini RM; Brickelmaier M; Wen D; Hess DM; Chen L; Grant D; Whitty A; Gill A; Lindner DJ; Pepinsky RB
Bioconjug Chem; 2006; 17(1):179-88. PubMed ID: 16417267
[TBL] [Abstract][Full Text] [Related]
6. APB-F1, a long-acting feline granulocyte colony-stimulating factor fusion protein, created by exploiting FL335, a chimeric Fab specific for feline serum albumin.
Chi HJ; Park M; Han JK; Kim SM; Kang S; Yang JH; Cha SH
Vet Immunol Immunopathol; 2021 Oct; 240():110322. PubMed ID: 34509747
[TBL] [Abstract][Full Text] [Related]
7. Further study on the specificity and incidence of neutralizing antibodies to interferon (IFN) in relapsing remitting multiple sclerosis patients treated with IFN beta-1a or IFN beta-1b.
Antonelli G; Simeoni E; Bagnato F; Pozzilli C; Turriziani O; Tesoro R; Di Marco P; Gasperini C; Fieschi C; Dianzani F
J Neurol Sci; 1999 Oct; 168(2):131-6. PubMed ID: 10526196
[TBL] [Abstract][Full Text] [Related]
8. Expression, purification, and characterization of rat interferon-beta, and preparation of an N-terminally PEGylated form with improved pharmacokinetic parameters.
Arduini RM; Li Z; Rapoza A; Gronke R; Hess DM; Wen D; Miatkowski K; Coots C; Kaffashan A; Viseux N; Delaney J; Domon B; Young CN; Boynton R; Chen LL; Chen L; Betzenhauser M; Miller S; Gill A; Pepinsky RB; Hochman PS; Baker DP
Protein Expr Purif; 2004 Apr; 34(2):229-42. PubMed ID: 15003256
[TBL] [Abstract][Full Text] [Related]
9. Improved pharmacokinetic properties of a polyethylene glycol-modified form of interferon-beta-1a with preserved in vitro bioactivity.
Pepinsky RB; LePage DJ; Gill A; Chakraborty A; Vaidyanathan S; Green M; Baker DP; Whalley E; Hochman PS; Martin P
J Pharmacol Exp Ther; 2001 Jun; 297(3):1059-66. PubMed ID: 11356929
[TBL] [Abstract][Full Text] [Related]
10. An IFN-beta-albumin fusion protein that displays improved pharmacokinetic and pharmacodynamic properties in nonhuman primates.
Sung C; Nardelli B; LaFleur DW; Blatter E; Corcoran M; Olsen HS; Birse CE; Pickeral OK; Zhang J; Shah D; Moody G; Gentz S; Beebe L; Moore PA
J Interferon Cytokine Res; 2003 Jan; 23(1):25-36. PubMed ID: 12639296
[TBL] [Abstract][Full Text] [Related]
11. Development and characterization of a novel long-acting recombinant follicle stimulating hormone agonist by fusing Fc to an FSH-β subunit.
Zhang YL; Guo KP; Ji SY; Liu XM; Wang P; Wu J; Gao L; Jiang TQ; Xu T; Fan HY
Hum Reprod; 2016 Jan; 31(1):169-82. PubMed ID: 26621853
[TBL] [Abstract][Full Text] [Related]
12. Development and biological activity of long-acting recombinant human interferon-α2b.
Zhang Q; Wang C; Ma F; Yao L; Gao H; Zhu L; Zheng L
BMC Biotechnol; 2020 Mar; 20(1):16. PubMed ID: 32169063
[TBL] [Abstract][Full Text] [Related]
13. [Expression in Pichia pastoris and properties of human serum albumin-interferon alpha2b chimera].
Chang SH; Gong X; Yang ZY; Wang TY; Ma GC; Ma QJ; Wu J
Sheng Wu Gong Cheng Xue Bao; 2006 Mar; 22(2):173-9. PubMed ID: 16607939
[TBL] [Abstract][Full Text] [Related]
14. Half-life extension using serum albumin-binding DARPin® domains.
Steiner D; Merz FW; Sonderegger I; Gulotti-Georgieva M; Villemagne D; Phillips DJ; Forrer P; Stumpp MT; Zitt C; Binz HK
Protein Eng Des Sel; 2017 Sep; 30(9):583-591. PubMed ID: 29088432
[TBL] [Abstract][Full Text] [Related]
15. Pulmonary administration of interferon Beta-1a-fc fusion protein in non-human primates using an immunoglobulin transport pathway.
Vallee S; Rakhe S; Reidy T; Walker S; Lu Q; Sakorafas P; Low S; Bitonti A
J Interferon Cytokine Res; 2012 Apr; 32(4):178-84. PubMed ID: 22191463
[TBL] [Abstract][Full Text] [Related]
16. Systematic mutational mapping of sites on human interferon-beta-1a that are important for receptor binding and functional activity.
Runkel L; deDios C; Karpusas M; Betzenhauser M; Muldowney C; Zafari M; Benjamin CD; Miller S; Hochman PS; Whitty A
Biochemistry; 2000 Mar; 39(10):2538-51. PubMed ID: 10704203
[TBL] [Abstract][Full Text] [Related]
17. An anti-TNFR1 scFv-HSA fusion protein as selective antagonist of TNF action.
Berger V; Richter F; Zettlitz K; Unverdorben F; Scheurich P; Herrmann A; Pfizenmaier K; Kontermann RE
Protein Eng Des Sel; 2013 Oct; 26(10):581-7. PubMed ID: 24006371
[TBL] [Abstract][Full Text] [Related]
18. Circumventing the heterogeneity and instability of human serum albumin-interferon-alpha2b fusion protein by altering its orientation.
Zhao HL; Xue C; Wang Y; Li XY; Xiong XH; Yao XQ; Liu ZM
J Biotechnol; 2007 Sep; 131(3):245-52. PubMed ID: 17698234
[TBL] [Abstract][Full Text] [Related]
19. Biological standardization of human interferon beta: establishment of a replacement world health organization international biological standard for human glycosylated interferon beta.
Meager A; Das RG
J Immunol Methods; 2005 Nov; 306(1-2):1-15. PubMed ID: 16226271
[TBL] [Abstract][Full Text] [Related]
20. Immunogenicity of an interferon-beta1a product.
Kauffman MA; Sterin-Prync A; Papouchado M; González E; Vidal AJ; Grossberg SE; Chuppa S; Odoriz B; Vrech C; Diez RA; Ferro HH
Int J Immunopathol Pharmacol; 2011; 24(2):499-504. PubMed ID: 21658324
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
